Drug Status Key

  • Preferred
  • On Formulary
  • Specialist Initiation
  • Shared Care
  • Hospital Only
  • Under Review
  • New on System

1.3.3 Chelates and complexes

Sucralfate®: Following reports of bezoar formation associated with sucralfate, the CSM has advised caution in seriously ill patients, especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying. De-Noltab® requires counselling on correct administration. Can blacken faeces and darken tongue.

De-Noltab® is only to be used as part of quadruple eradication therapy.

Please note, sample information has been entered into Chapters 1 and 2 only and although fairly clinically accurate, it is not guaranteed. The information was entered during April and May 2017 and drugs will have subsequently been randomly added during telephone demonstrations.

Show All